This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA has announced several guidelines and plans to hold at least one public meeting on digital healthtechnologies (DHTs) to be used in drug clinical trials by the end of the year. Drugdevelopment process questions the reliability and accuracy of DHT products.
Digital HealthTechnologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
NEW YORK–(BUSINESS WIRE)– Deliberate AI , a digital healthtechnology company that delivers precision measurement of mental health through AI, today announced its inclusion in the U.S. Food and Drug Administration (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital healthtechnology and develop digital biomarkers for Parkinson’s disease.
Koneksa’s innovative digital model aims to address limitations in existing functional status assessments by leveraging digital healthtechnologies (DHTs) for both objective and self-reported outcomes. Chief Medical Officer, Koneksa. Chief Scientific Officer, Koneksa.
Digital healthtechnologies (DHT) can collect objective, multi-dimensional data passively and remotely with a limited burden for clinical trial participants, providing a way to capture previously inaccessible insights to support drugdevelopment and commercialization.
This patient-centric approach ensures that new treatments are not only effective but that they improve quality of life, enhance adherence to therapy, and ultimately achieve better health outcomes.
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drugdevelopment processes with the implementation of newer technologies.
We’re on a mission to revolutionize drugdevelopment in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. Beacon’s mobile EEG will join more than a dozen digital healthtechnologies that are already integrated into the Koneksa solution.
This pilot study represents a critical step in leveraging digital healthtechnology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By
We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.” Schwartz, A.L, Morris, A.M., Halpern, S.D., N Engl J Med 2023; 388:1252-1254.
The funding speaks to the global nature of pre-approval access and its increasing importance in the drugdevelopment process. “ Our mutual dedication to building new approaches to pharmaceutical drugdevelopment and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably. .
Despite a history of drugdevelopment failures in the field, recent work provides reason for optimism, showing a possible therapeutic arsenal to limit disease progression at an early stage.
Blockchain can also ensure the accuracy of the data exchanged among entities, something a HIE (health information exchange) cannot do. Blockchain technology’s potential impact on the life sciences industry (drugdevelopment, distribution and prescribing) is significant.
When it comes to incorporating new technology into drugdevelopment and clinical practice, the best place to start is with the patients. Each article opens with an actual clinical case where wearable data was used to care for a patient.
Regulatory Landscape: Regulatory Clarity: Clearer regulatory frameworks for digital healthtechnologies will foster investor confidence and higher valuations. Companies specialising in AI-driven medical imaging, drugdevelopment, and predictive analytics are likely to see substantial valuation increases.
In 2025, B2C2B models are poised to become increasingly prominent in healthcare, driven by several key factors: Digital Health Boom: The rapid growth of digital healthtechnologies, such as telehealth, wearable devices, and AI-powered diagnostics, is creating new opportunities for B2C2B companies to reach both patients and healthcare providers.
The increasing adoption of digital healthtechnologies, the growing importance of AI and ML, and the evolving regulatory landscape will continue to shape the deal landscape. Increased Regulatory Scrutiny: Increased regulatory scrutiny may impact M&A activity, particularly in areas like data privacy and antitrust.
Goal: Empower individuals to manage their health, prevent diseases, and access healthcare services efficiently. Healthtech Focus: Broader term encompassing the use of technology to improve the overall healthcare delivery system. Drug discovery: AI-powered tools will accelerate the drugdevelopment process by analyzing vast datasets.
Whether it is in operational delivery, service provision, patient enablement or drug discovery, technology has continued to create wide scale impact as we shift towards a post-pandemic world. In fact, Exscientia stands by the claim that all drugs in the future will be made using AI. .
With access to these collective resources and by capitalizing on existing biosamples as well as clinical data, including that from digital healthtechnology, researchers will focus on identifying and validating biomarkers and therapeutic targets specific to ALS.
Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven Technologies NEW YORK–(BUSINESS WIRE)– Massive Bio Inc.,
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content